Guides
Is Sermorelin Legal? What the FDA Actually Says in 2026
Sermorelin's only FDA-approved product was discontinued for business reasons, not safety — and it isn't on any current FDA compounding list. Here's what that actually means, with the primary sources.
Sermorelin shows up on Houston clinic menus almost as often as BPC-157 — usually marketed as an anti-aging or “growth hormone optimization” injection. Its regulatory story is different from BPC-157’s, though, and less discussed: sermorelin isn’t under active FDA review at all. It’s just never been addressed, which is its own kind of red flag.
What it is
Sermorelin acetate is a synthetic analog of growth hormone-releasing hormone (GHRH) — the signal the hypothalamus sends the pituitary gland to release the body’s own growth hormone. It is not growth hormone itself.
The FDA status, in order
1990–1997: Sermorelin acetate was FDA-approved as Geref, sold by Serono (later EMD Serono). The original application (NDA 019863) was approved December 28, 1990, for diagnostic use in evaluating growth hormone secretion; a second application (NDA 020443) was approved September 26, 1997, for treating pediatric growth hormone deficiency. Both were real, FDA-reviewed drug approvals — this is not a research-only substance that never had a path to legitimacy.
Discontinuation: Geref is no longer marketed. FDA’s own Drugs@FDA database carries an explicit annotation on both approvals: a Federal Register determination that the product “was not discontinued or withdrawn for safety or effectiveness reasons.” That matters — it distinguishes sermorelin from a drug pulled because it hurt people. We also checked DailyMed, the National Library of Medicine’s database of current FDA-approved drug labeling: as of this writing it returns zero results for sermorelin. There is no FDA-approved sermorelin product on the market today, from any manufacturer.
Where it sits on FDA’s compounding lists — nowhere. Section 503A lets a compounding pharmacy use a bulk substance if it has a USP/NF monograph, is a component of an FDA-approved drug product, or appears on FDA’s 503A Bulks List when neither of those applies. We checked the 503A Bulks List directly: sermorelin is not on it. We also checked FDA’s Category 2 list of substances with identified safety risks: sermorelin is not on that either. And unlike BPC-157, KPV, TB-500, and MOTs-C — all under formal review at the FDA’s Pharmacy Compounding Advisory Committee meeting on July 23–24, 2026 — sermorelin was not on that agenda. It isn’t in FDA’s active nomination pipeline at all.
What that leaves: a compounder’s practical argument for using sermorelin rests on the “component of an FDA-approved drug product” pathway, pointing back to Geref. Whether a discontinued approval still qualifies a substance for that pathway is a genuinely unsettled question — FDA hasn’t published guidance resolving it for sermorelin specifically, the way it has worked through BPC-157 via the interim category system. That’s a materially different kind of gray area than BPC-157’s: BPC-157 is being actively evaluated; sermorelin has simply never come up.
What this means for a clinic menu
“Sermorelin was FDA-approved” is true, and clinics that say it lean on that fact. What they usually don’t mention: the approved product was for a narrow diagnostic and pediatric-deficiency use, it’s been off the market for years, and the substance sold today has no FDA-approved indication for anti-aging, weight loss, or general wellness in adults — the uses it’s actually marketed for.
Red flags we check for
Indications that don’t match the approval history. Geref was approved to test for and treat growth hormone deficiency, not for anti-aging, fat loss, or muscle building in adults with normal pituitary function. A clinic selling it for those uses is marketing outside anything the FDA ever reviewed.
No documented patient-specific need. The same standard applies here as everywhere else in our methodology: compounding is supposed to serve an individual patient’s documented medical circumstance, not function as a standing wellness product sold to anyone who asks.
No named, NPI-verified prescriber. If a clinic can’t tell you who is prescribing sermorelin and under what clinical rationale, the “medical” framing isn’t real — the same test we apply to every clinic in this directory.
Browse our verified GLP-1 and peptide clinics in Houston, read what disqualifies a clinic and why, and see our full verification standard.
Sources: U.S. Food and Drug Administration, Drugs@FDA data via the openFDA API (api.fda.gov/drug/drugsfda.json), records for NDA 019863 and NDA 020443 (Geref, sermorelin acetate, EMD Serono) — marketing status “Discontinued” with Federal Register determination that discontinuation was not for safety or effectiveness reasons, retrieved September 14, 2026. National Library of Medicine, DailyMed API (dailymed.nlm.nih.gov), search for “sermorelin” — zero currently labeled products, database as published September 11, 2026, retrieved September 14, 2026. FDA, “Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act” (503A Bulks List; sermorelin not present), retrieved September 14, 2026. FDA, “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks” (Category 2 list; sermorelin not present), retrieved September 14, 2026. FDA, “July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee” (agenda substances: BPC-157, KPV, TB-500, MOTs-C, Emideltide/DSIP, Semax, Epitalon — sermorelin not on the agenda), retrieved September 14, 2026.
This article is independent editorial content, not medical advice. See our medical disclaimer.